[go: up one dir, main page]

MA48743A - Composés et méthodes de traitement d'infections bactériennes - Google Patents

Composés et méthodes de traitement d'infections bactériennes

Info

Publication number
MA48743A
MA48743A MA048743A MA48743A MA48743A MA 48743 A MA48743 A MA 48743A MA 048743 A MA048743 A MA 048743A MA 48743 A MA48743 A MA 48743A MA 48743 A MA48743 A MA 48743A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
methods
bacterial infections
infections
Prior art date
Application number
MA048743A
Other languages
English (en)
Inventor
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Satenig Guler
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo Velez-Vega
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of MA48743A publication Critical patent/MA48743A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA048743A 2017-05-08 2018-05-08 Composés et méthodes de traitement d'infections bactériennes MA48743A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08

Publications (1)

Publication Number Publication Date
MA48743A true MA48743A (fr) 2020-04-08

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048743A MA48743A (fr) 2017-05-08 2018-05-08 Composés et méthodes de traitement d'infections bactériennes

Country Status (27)

Country Link
US (1) US11046694B2 (fr)
EP (1) EP3630111B1 (fr)
JP (1) JP7058322B2 (fr)
KR (1) KR102611447B1 (fr)
CN (1) CN110709081B (fr)
AU (1) AU2018266640B2 (fr)
CY (1) CY1125340T1 (fr)
DK (1) DK3630111T3 (fr)
EA (1) EA038393B1 (fr)
ES (1) ES2907858T3 (fr)
HR (1) HRP20220231T1 (fr)
HU (1) HUE057592T2 (fr)
IL (1) IL270380B (fr)
LT (1) LT3630111T (fr)
MA (1) MA48743A (fr)
MX (1) MX385203B (fr)
MY (1) MY201377A (fr)
NZ (1) NZ758200A (fr)
PE (1) PE20200333A1 (fr)
PH (1) PH12019502509A1 (fr)
PL (1) PL3630111T3 (fr)
PT (1) PT3630111T (fr)
SG (1) SG11201909443YA (fr)
SI (1) SI3630111T1 (fr)
SM (1) SMT202200110T1 (fr)
TW (1) TWI791018B (fr)
WO (1) WO2018208769A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
FI3833665T3 (fi) 2018-08-09 2023-10-09 Antabio Sas Diatsabisyklo-oktanoneja seriini-beeta-laktamaasien inhibiittoreina
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
EP4146651A4 (fr) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences Composés substitués de sulfonylamidine et leur utilisation en tant qu'inhibiteurs de bêta-lactamase
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (fr) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Composés et méthodes pour traiter des infections bactériennes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU699465B2 (en) 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
AU2009206119C1 (en) 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (fr) 2008-06-19 2015-09-23 Astra Zeneca Holding France Utilisation de (1r, 2s, 5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy) -, sel monosodique en tant que réactif de diagnostic pour la détection de sérines bêta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
WO2013014497A1 (fr) 2011-07-26 2013-01-31 Wockhardt Limited Compositions pharmaceutiques comprenant un antibiotique bêta-lactame, du sulbactam et un inhibiteur de bêta-lactamase
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
PL2748165T3 (pl) 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
ES2606059T3 (es) 2011-08-30 2017-03-17 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2013038330A1 (fr) 2011-09-13 2013-03-21 Wockhardt Limited Composés azotés et leur utilisation
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) * 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
SG11201406120SA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
MY174523A (en) 2012-05-30 2020-04-23 Meiji Seika Pharma Co Ltd ?-lactamase inhibitor and process for preparing the same
EP3360877B1 (fr) 2012-08-25 2021-02-17 Wockhardt Limited Derives de 1,6- diazabicyclo [3,2,1]octan- 7- one en tant que composés antibactériens
AU2013308128B2 (en) 2012-09-03 2017-11-02 Wockhardt Limited Antibacterial compositions
UA115683C2 (uk) 2013-02-06 2017-12-11 Пфайзер Енті-Інфектівз Аб Комбінована терапія для лікування госпітальної пневмонії
WO2014141132A1 (fr) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. Nouveaux composés hétérocycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de β-lactamase
MY196240A (en) 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
EP3512851B1 (fr) 2016-09-16 2022-07-06 Entasis Therapeutics Limited Composés inhibiteurs de bêta-lactamase

Also Published As

Publication number Publication date
EA038393B1 (ru) 2021-08-20
SMT202200110T1 (it) 2022-05-12
MX2019013291A (es) 2020-01-15
LT3630111T (lt) 2022-03-10
KR20200005586A (ko) 2020-01-15
AU2018266640A1 (en) 2019-11-07
MX385203B (es) 2025-03-14
PE20200333A1 (es) 2020-02-14
CN110709081A (zh) 2020-01-17
DK3630111T3 (en) 2022-03-14
PH12019502509A1 (en) 2020-07-13
CA3059773A1 (fr) 2018-11-15
MY201377A (en) 2024-02-21
US20200165251A1 (en) 2020-05-28
US11046694B2 (en) 2021-06-29
ES2907858T3 (es) 2022-04-26
EA201992370A1 (ru) 2020-03-10
SG11201909443YA (en) 2019-11-28
PL3630111T3 (pl) 2022-05-23
IL270380B (en) 2022-06-01
SI3630111T1 (sl) 2022-05-31
KR102611447B1 (ko) 2023-12-06
EP3630111A1 (fr) 2020-04-08
WO2018208769A1 (fr) 2018-11-15
TWI791018B (zh) 2023-02-01
HUE057592T2 (hu) 2022-05-28
CY1125340T1 (el) 2024-02-16
HRP20220231T1 (hr) 2022-04-29
AU2018266640B2 (en) 2022-03-03
TW201843152A (zh) 2018-12-16
JP7058322B2 (ja) 2022-04-21
PT3630111T (pt) 2022-03-01
BR112019023130A2 (pt) 2020-05-26
JP2020519687A (ja) 2020-07-02
NZ758200A (en) 2025-12-19
CN110709081B (zh) 2023-09-22
EP3630111B1 (fr) 2021-11-24

Similar Documents

Publication Publication Date Title
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3426248A4 (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA46102A (fr) Composés de tétracycline et méthodes de traitement
EP3607072A4 (fr) Compositions et méthodes de traitement de la phénylcétonurie
MA48743A (fr) Composés et méthodes de traitement d'infections bactériennes
MA50267A (fr) Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr)
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
MA48730A (fr) Compositions et méthodes de traitement de synucléinopathies
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
EP3589659A4 (fr) Composés et méthodes de traitement du cancer
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3641746A4 (fr) Méthodes et compositions pour le traitement d'une infection microbienne
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3927428A4 (fr) Méthodes de traitement d'affections respiratoires